Napoli

• A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending
  2024-514248-95-00 5 Uncontrolled Asthma
• Personalized antibiotic TREATment for febrile Urinary Tract Infections in children (TREAT-UTI study): multicenter randomized controlled tria … Pending
  2025-520622-38-00 5 Urinary Tract Infections
• A Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fi … Pending
  2025-523660-21-00 5 hemophilia A
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo … Recruiting
  2025-522093-36-00 10 2026-05-20 Cancer cachexia
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting
  2023-503699-25-00 5 2024-07-15 Progressive Pulmonary Fibrosis
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting
  2023-503697-21-01 5 2024-06-24 Idiopathic pulmonary fibrosis
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Pilot Study to Evaluate Safety and Efficacy of PolyCore, a Ternary Combination of Xylitol, L-Carnitine and Polydextrin, to Treat End-Stage K … Recruiting
  2024-519366-52-00 4 2026-02-17 End-Stage Kidney Disease
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting
  2024-519669-23-00 4 2025-09-29 Patients with metastatic colorectal cancer (mCRC) RAS-mutant
• Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MM … Recruiting
  2024-511993-55-00 4 2025-09-18 bile acid diarrhoea (BAD)
• Myocarditis Therapy with Steroids in patients with a Mildly Reduced ejection fraction (MYTHS-MR) Recruiting
  2022-501547-33-01 11 2024-12-24 Acute myocarditis
• Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h … Recruiting
  2023-509717-36-00 5 2024-12-16 AF patients who have undergone successful PCI
• Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose i … Recruiting
  2024-518096-57-00 5 2024-11-11 Septic shock
• Trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant a … Recruiting
  2023-504169-22-02 5 2024-07-31 Severe cardiac inflammation
• An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients wit … Recruiting
  2024-511635-94-00 4 2022-07-11 Relapsed or Refractory Plasmablastic lymphoma
• Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 par … Recruiting
  2024-517864-49-01 5 2020-09-08 Autosomal Dominant Polycystic Kidney Disease
• Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm … Recruiting
  2024-517200-10-00 4 2020-01-31 Advanced non-small-cell lung cancer
• Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva … Recruiting
  2024-513372-18-00 4 2019-10-18 Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
• CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA … Recruiting
  2024-518987-11-00 4 2019-06-12 ADCC
• L19IL2/L19TNF in skin cancer patients Ended recruitment
  2024-518531-10-00 4 2024-11-26 Phase II, open label, multicentric, proof-of-principle basket trial in
• RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVAL … Ended recruitment
  2024-513721-23-00 4 2022-12-15 ADVANCED TRIPLE NEGATIVE BREAST CANCER
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study) Ended recruitment
  2024-518909-18-00 5 2021-03-23 HIV-1 infected individuals currently taking an INSTI-based three-drug

Showing 1–24 of 26 trials